S
Sofinnova Investments, Inc.
+ Con en carteraMANE
+7.79%
Rentabilidad a 3 meses
$108.820
-5.909 (-5.43%)Al cierre
Loading chart…
- Máximo
- 114.250
- Apertura
- 114.190
- Precio medio ponderado por volumen
- 109.86
- Volumen
- 672.94K
- Capitalización
- —
- Mínimo
- 106.510
- Importe
- 73.93M
- EV/EBITDA, TTM
- 0.00
Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.
Análisis de IA of Veradermics Inc (MANE)
ComprarVeraDermics, Inc. (MANE) is a good buy right now due to its recent positive Phase 2 trial results for its hair loss treatment, which led to a stock increase of over 12%. The current price is $130.90, and analysts have set price targets as high as $182, indicating significant upside potential. However, the company has reported net losses, with a current net income of -30,011,000 USD for Q1 2026, which poses a risk to consider.
Métricas de valoración
El PER previsto actual de Veradermics Inc (MANE) es 0.00, frente a su media de 5 años de .
Ballenas con MANE en cartera
Cronología de eventos
Noticias
8.509-03NewsfilterVeradermics to Participate in Upcoming Investor Conferences
- 9.008-11Newsfilter
VDPHL01 Shows Promising Results for Female Hair Loss Treatment
8.507-18NASDAQ.COMMultiple Biopharma Companies Receive FDA Approvals
- 9.007-17Newsfilter
Veradermics Presents Phase 2/3 Data for VDPHL01 in Hair Loss Treatment
2.007-16NASDAQ.COMBiotech Stocks Surge Amid Positive Developments
Preguntas frecuentes sobre MANE, respondidas por Alphio AI
Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL. It operates in the Healthcare sector.
VeraDermics, Inc. (MANE) is a good buy right now due to its recent positive Phase 2 trial results for its hair loss treatment, which led to a stock increase of over 12%. The current price is $130.90, and analysts have set price targets as high as $182, indicating significant upside potential. However, the company has reported net losses, with a current net income of -30,011,000 USD for Q1 2026, which poses a risk to consider.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.